<DOC>
	<DOCNO>NCT00634504</DOCNO>
	<brief_summary>The purpose study investigate whether administration Voraxaze reduce exposure leucovorin active metabolite level achieve patient receive Voraxaze .</brief_summary>
	<brief_title>Open-label Leucovorin Pharmacokinetic Study Patients Receiving High Dose Methotrexate With Without Voraxaze</brief_title>
	<detailed_description />
	<mesh_term>Osteosarcoma</mesh_term>
	<mesh_term>Methotrexate</mesh_term>
	<criteria>Receiving Highdose methotrexate ( HDMTX ) without risk methotrexate ( MTX ) toxicity , impaired renal function , delay MTX elimination Require intravenous leucovorin Arm A : allergic reaction lactose Arm A : hereditary fructose galactose intolerance Arm B : delay elimination MTX</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2014</verification_date>
	<keyword>high dose methotrexate</keyword>
	<keyword>Voraxaze</keyword>
	<keyword>leucovorin</keyword>
	<keyword>delay elimination</keyword>
	<keyword>methotrexate toxicity</keyword>
	<keyword>rescue</keyword>
	<keyword>renal insufficiency</keyword>
</DOC>